IL-7–dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL
João T. Barata(Instituto Gulbenkian de Ciência), Angelo A. Cardoso(Centro Infantil Boldrini), Adolfo A. Ferrando(Regeneron (United States)), José Andrés Yunes(Universidade Estadual de Campinas (UNICAMP)), Lisa A. Moreau(Harvard University), Stephen E. Sallan, J. Pedro Veiga(Harvard University), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), A. Thomas Look, Lee M. Nadler(Dana-Farber Cancer Institute)
Cited by 44
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k